Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 1.64 USD -5.2% Market Closed
Market Cap: 436.5m USD

EV/EBITDA
Enterprise Value to EBITDA

-1.2
Current
-2.2
Median
6.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.2
=
Enterprise Value
321m USD
/
EBITDA
-264.7m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
Average EV/EBITDA: 39.7
Negative Multiple: -1.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 056.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
11%
1.6
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158.4
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
807%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.2
2-Years Forward
EV/EBITDA
-1.3
3-Years Forward
EV/EBITDA
-1.7